Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Horizon Pharma AG

Division of Horizon Therapeutics PLC
www.nitec-pharma.com

Latest From Horizon Pharma AG

Genmab Cash Pile To Grow With Another Darzalex OK

The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.

Approvals Cancer

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.

Pricing Debate Legislation

Big Pharma Defuses Drug Pricing Landmines On Capitol Hill

Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.

Pricing Debate Legislation

Cash-guzzling Horizon prices new offering

Horizon Pharma has priced a public offering of common stock and warrants and expects to raise $70 million in net proceeds, or $81 million if an over-allotment option is fully exercised. The offering, which is expected to close on 25 September, will involve the sale of units consisting of one share and a warrant to purchase 0.5 shares priced at $3.50. The company's share price has tumbled by 24% from $4.58 on 19 September before it disclosed its planned offering to $3.49 in mid-morning trading on 21 September following the pricing. The company's market cap was $118 million on 21 September 2012.

Orthopedics Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Nitec Pharma AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • Anders Harfstrand, MD, PhD, CEO
    Harry Welten, CFO
    Jochen Mattis, EVP, Sales & Mktg., Bus. Dev.
    Achim Schaffler, PhD, EVP, R&D/Technical Ops.
  • Contact Info
  • Horizon Pharma AG
    Phone: (41) 61 715 20 40
    Kägenstrasse 17
    Reinach, 4153
    Switzerland
UsernamePublicRestriction

Register